Patents by Inventor Gian Luca Araldi

Gian Luca Araldi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7410991
    Abstract: The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: August 12, 2008
    Assignee: Laboratoires Serono S.A.
    Inventors: Gian Luca Araldi, Yihua Liao, Adulla P. Reddy, Zhong Zhao
  • Publication number: 20080153810
    Abstract: The present invention relates to novel compounds, in particular, novel indazole that may be used as melanin concentrating hormone receptor ligands, methods of preparing such compounds, compositions containing such compounds, and methods of using such compounds to treat MCH related disorders.
    Type: Application
    Filed: November 14, 2007
    Publication date: June 26, 2008
    Applicant: Forest Laboratories Holdings Limited
    Inventors: Matthew Ronsheim, Gian-Luca Araldi
  • Publication number: 20080146547
    Abstract: The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: November 14, 2007
    Publication date: June 19, 2008
    Applicant: Forest Laboratories Holdings Limited
    Inventors: Gian-Luca Araldi, Matthew Ronsheim, Melanie Ronsheim
  • Publication number: 20080114051
    Abstract: Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound.
    Type: Application
    Filed: November 21, 2007
    Publication date: May 15, 2008
    Applicant: LABORATOIRES SERONO S.A.
    Inventors: Yihua LIAO, Zhong Zhao, Gian Luca Araldi
  • Publication number: 20080058350
    Abstract: The present invention relates to imidazopyridine and imidazopyrimidine derivatives that act as cannabinoid receptor ligands, e.g., CB2 ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
    Type: Application
    Filed: August 27, 2007
    Publication date: March 6, 2008
    Applicant: Forest Laboratories Holdings Limited
    Inventors: Gian-Luca Araldi, Matthew Ronsheim, Nhut Diep
  • Patent number: 7335680
    Abstract: Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: February 26, 2008
    Assignee: Laboratoires Serono SA
    Inventors: Yihua Liao, Zhong Zhao, Gian Luca Araldi
  • Publication number: 20080009491
    Abstract: The present invention relates to pyridoimidazole derivatives that act as cannabinoid receptor ligands, e.g., CB2 ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
    Type: Application
    Filed: July 2, 2007
    Publication date: January 10, 2008
    Applicant: FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Matthew Ronsheim, Gian-Luca Araldi
  • Publication number: 20080009632
    Abstract: Methods for the synthesis of heterocyclic compounds including N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: July 3, 2007
    Publication date: January 10, 2008
    Applicant: Forest Laboratories Holdings Limited
    Inventors: Gian-Luca Araldi, Melanie Ronsheim, Nhut Diep, Shao Zhou
  • Publication number: 20070281918
    Abstract: The present invention relates to pyridoazepine derivatives that act as 5-HT ligands, e.g., 5-HT2C ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
    Type: Application
    Filed: May 23, 2007
    Publication date: December 6, 2007
    Applicant: Forest Laboratories Holdings Limited
    Inventors: Gian-Luca Araldi, Alexander Bischoff, Nhut Diep
  • Patent number: 7276531
    Abstract: A gamma-lactam diene of Formula I: which is particularly useful as a medicament for the treatment of various disorders such as asthma, hypertension, osteoporosis, sexual dysfunction and fertility disorders.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: October 2, 2007
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Gian Luca Araldi, Srinivasa Karra, Zhong Zhao, Nadia Brugger
  • Patent number: 7202279
    Abstract: The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.
    Type: Grant
    Filed: February 8, 1999
    Date of Patent: April 10, 2007
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Alan I. Faden, Gian Luca Araldi
  • Patent number: 7157596
    Abstract: The present invention provides compounds which inhibit serine protease activity of matriptase or MTSP1. Also provided are pharmaceutical compositions comprising those compounds and methods of using the compounds and pharmaceutical compositions to treat conditions ameliorated by inhibition of matriptase or MTSP1.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: January 2, 2007
    Inventors: Joseph E. Semple, Gary S. Coombs, John E. Reiner, Edgar O Ong, Gian Luca Araldi
  • Publication number: 20040254233
    Abstract: The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.
    Type: Application
    Filed: April 16, 2004
    Publication date: December 16, 2004
    Inventors: Gian Luca Araldi, Yihua Liao, Adulla P. Reddy, Zhong Zhao
  • Patent number: 6825211
    Abstract: The present invention provides bicyclic metabotropic glutamate receptor ligands, as well as compositions comprising such ligands, and methods for their use.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: November 30, 2004
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Darryl Hugh Steensma, Werner Tueckmantel, Gian Luca Araldi
  • Patent number: 6806281
    Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and Y have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease or depression comprising administering a compound of formula I, to a mammal in need of such treatment.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: October 19, 2004
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Gian Luca Araldi
  • Patent number: 6797504
    Abstract: The present invention provides compounds which inhibit serine protease activity of matriptase or MTSP1. Also provided are pharmaceutical compositions comprising those compounds and methods of using the compounds and pharmaceutical compositions to treat conditions ameliorated by inhibition of matriptase or MTSP1. The invention provides recombinant serine protease domains and methods of using peptides comprising a recombinant serine protease domain to screen for compounds that inhibit serine protease activity of matriptase or MTSP1.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: September 28, 2004
    Assignee: Dendreon San Diego LLC
    Inventors: Edwin L. Madison, Joseph Edward Semple, Gary Samuel Coombs, John Eugene Reiner, Edgar O. Ong, Gian Luca Araldi
  • Patent number: 6610743
    Abstract: The present invention provides bicyclic metabotropic glutamate receptor ligands, as well as compositions comprising such ligands, and and methods for their use.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: August 26, 2003
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Darryl Hugh Steensma, Werner Tueckmantel, Gian Luca Araldi
  • Patent number: 6605621
    Abstract: The invention provides compounds of formula(I): X—L—X1  (I) wherein X, L, and X1 have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: August 12, 2003
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Gian Luca Araldi, Amir P. Tamiz
  • Publication number: 20030144289
    Abstract: The invention provides compounds of formula (I):
    Type: Application
    Filed: July 30, 2002
    Publication date: July 31, 2003
    Inventors: Alan P. Kozikowski, Gian Luca Araldi, Amir P. Tamiz
  • Publication number: 20030144319
    Abstract: The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
    Type: Application
    Filed: November 14, 2002
    Publication date: July 31, 2003
    Inventors: Christopher F. Bigge, Gian Luca Araldi, Sui Xiong Cai, Anthony P. Guzikowski, Donald Lamunyon, Nancy C. Lan, Zhang-Lin Zhou, John F.W. Keana